Advertisement

Type 2 Diabetes

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

Research Summaries

Research summary
surgical tools
Research summary
Gastric Bypass Surgery Improves Continued Type 2 Diabetes Remission, Even After Weight Recurrence
03/22/2024

Jessica Ganga

Jessica Ganga
Researchers sought to determine whether patients with type 2 diabetes and obesity experience continued type 2 diabetes remission.
03/22/2024
FDA Alert
shutterstock
FDA Alert
FDA Approves Semaglutide For Reducing Serious Cardiovascular Events Among Adults With Heart Disease and Obesity, Overweight
03/21/2024

Anthony Calabro, MA

Anthony Calabro, MA
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
03/21/2024
Roundtable Wrap-Up
carol
Roundtable Wrap-Up
Continuous Glucose Monitoring: What Should Clinicians Do With All That Data?
01/12/2024

Carol Wysham, MD, Hope Warshaw, MMSc, RD, CDCES, BC-ADM, Eugene E. Wright, Jr., MD

Carol Wysham, MD, Hope Warshaw, MMSc, RD, CDCES, BC-ADM, Eugene E. Wright, Jr., MD ...
In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing people with diabetes, the importance of diabetes self-care and...
01/12/2024
Research Summary
eye
Research Summary
Semaglutide May Not Worsen Diabetic Retinopathy in Patients Using The Medication
01/04/2024

Jessica Ganga

Jessica Ganga
Researchers evaluated the popular diabetes medication, semaglutide, to determine whether it causes or worsens diabetic retinopathy in patients using the medication. Their findings were presented at AAO 2023...
01/04/2024
Research Summary
rs
Research Summary
Semaglutide Provides Benefits for Patients With HFpEF and Obesity
11/22/2023

Anthony Calabro, MA

Anthony Calabro, MA
Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.
11/22/2023
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
FDA Alert
FDA Alert
FDA Alert
FDA Approves Two Medications to Treat Pediatric Patients With Type 2 Diabetes
08/10/2023

Jessica Ganga

Jessica Ganga
The FDA has approved empagliflozin, and empagliflozin and hydrochloride to help manage type 2 diabetes in pediatric patients.
08/10/2023
Research Summary
liver
Research Summary
Guideline Update from the American Diabetes Association for the Detection, Management of Patients With Diabetes, Nonalcoholic Fatty Liver Disease
06/28/2023
Based on recent scientific knowledge, the American Diabetes Association (ADA) released a set of updates including recommendations for the detection and management of nonalcoholic fatty liver disease in...
06/28/2023
Research Summary
Research Summary
Most Adults With Diabetes Can Use GLP-1 RAs, SGLT-2 Inhibitors But Don't
04/17/2023
Researchers set out to determine the percentage of people in the United States with type 2 diabetes who meet the recommended criteria to use GLP-1 receptor agonists and SGLT-2 inhibitors as well as patients...
04/17/2023
Research Summary
Research Summary
Treatment for Type 2 Diabetes Reduces Major CV Events in Men
02/28/2023
The researchers evaluated the effects of two medications used for type 2 diabetes patients on reducing major cardiovascular events in both men and women.
02/28/2023